Substandard Drugs: Proposed Licence Suspension, CAPA and Regulatory Capacity

What the proposed enforcement framework changes

Under the existing provisions described by the Ministry, suspension or cancellation follows a prescribed regulatory procedure, including a show-cause notice. The Ministry identifies a possible interval between an NSQ finding and regulatory action, during which the medicine may remain in circulation and recall may become more difficult.

The proposal would enable the Central Licensing Approving Authority or the State Licensing Authority to immediately suspend the manufacturing licence of the concerned drug upon receiving a government analyst’s report identifying failure on specified critical quality parameters. This is a proposed protective intervention, not automatic permanent cancellation.

• The specified parameters are assay, dissolution, related substances, impurities and sterility.
• The reported trigger concerns these critical parameters, not every possible category of NSQ finding.
• The source describes suspension of the manufacturing licence of the concerned drug; it does not establish automatic closure of the entire manufacturing site.
• The consultation period runs from the date on which copies of the Gazette containing the draft rules are made available to the public.

Why the selected quality parameters matter

These parameters assess whether a medicine contains the required amount of active ingredient, releases it appropriately, remains within permitted limits for unwanted substances and, where applicable, meets sterility requirements. Failures can compromise treatment or expose patients to avoidable harm.

An NSQ finding denotes failure to meet prescribed quality standards. It should not automatically be equated with a spurious drug: quality non-compliance and falsified identity are distinct regulatory concerns.

• Assay concerns the quantity or potency of the active ingredient.
• Dissolution assesses the rate and extent of release of the active ingredient into a test medium.
• Related substances and impurity tests assess unwanted chemical components, including relevant degradation products.
• Sterility testing is critical for products required to be sterile.

CAPA makes restoration conditional on fixing the cause

The suspension would continue until the manufacturer conducts an effective root cause analysis and implements appropriate Corrective and Preventive Action, or CAPA, to the satisfaction of the licensing authority. Restoration would follow implementation and regulatory verification of those measures.

This moves enforcement beyond a temporary interruption towards correction of the underlying quality system. A credible response should explain why the failure occurred, correct the deficiency and demonstrate safeguards against recurrence; merely submitting an assurance should not substitute for verified compliance.

• Root cause analysis identifies the underlying reason for the quality failure.
• Corrective action addresses the identified failure and its cause.
• Preventive action strengthens controls against recurrence or similar failures.
• Regulatory verification provides an independent check before suspension is revoked.

Centre-State coordination and administrative fairness

Consequential amendments to Form 13, concerning the government analyst’s test report, would provide for endorsement of the report to the DCGI, the State or Union Territory Licensing Authority responsible for the manufacturing site, and the manufacturer and marketer. This seeks to reduce communication delays and strengthen accountability across jurisdictions and the supply chain.

The constitutional context combines State responsibility for public health with the Concurrent List entry concerning drugs and poisons. The proposal therefore requires operational federalism: common testing standards, rapid information exchange and coordinated enforcement, rather than central rule-making alone.

Immediate protective action should also be accompanied by clear reasons, dependable evidence and prompt opportunities for review. The supplied report does not specify a new appeal or post-suspension hearing mechanism; these procedural safeguards should be examined during consultation.

• Licensing authorities need sufficient inspection and technical capacity to verify CAPA.
• Laboratory competence and sample integrity are essential because the analyst’s report would trigger immediate action.
• Manufacturers and marketers should receive clear information about the affected drug and required response.

Patient protection must include recall and continuity of treatment

Suspending manufacture does not, by itself, establish that every affected batch already in distribution has been retrieved. Effective implementation should connect licence action with traceable, risk-based recall and clear communication to hospitals, pharmacies and procurement agencies.

Enforcement may also constrain supply where alternative quality-assured sources are limited. The appropriate response is to arrange safe substitutes and monitor availability, not to permit continued supply of unsafe medicines or weaken quality standards.

• Map affected batches and their distribution to support retrieval.
• Identify quality-assured alternative suppliers for essential medicines.
• Communicate with clinicians so that patients do not interrupt necessary treatment without medical advice.
• Distinguish the drug or batches implicated by evidence from unaffected products when communicating regulatory action.